187 related articles for article (PubMed ID: 35777718)
1. Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent.
Luo W; Huang Z; Xu D; Yang M; Zhu Y; Shen L; Chen S; Tao X; Bin W; Hu Y; Franzblau SG; Jiang N; Wei Y; Wei X; Ding CZ
Bioorg Med Chem Lett; 2022 Sep; 72():128871. PubMed ID: 35777718
[TBL] [Abstract][Full Text] [Related]
2. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
Kwon YS; Jeong BH; Koh WJ
Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
[TBL] [Abstract][Full Text] [Related]
3. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
4. Delamanid: first global approval.
Ryan NJ; Lo JH
Drugs; 2014 Jun; 74(9):1041-5. PubMed ID: 24923253
[TBL] [Abstract][Full Text] [Related]
5. Profile of delamanid for the treatment of multidrug-resistant tuberculosis.
Szumowski JD; Lynch JB
Drug Des Devel Ther; 2015; 9():677-82. PubMed ID: 25678771
[TBL] [Abstract][Full Text] [Related]
6. Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis.
Thakare R; Soni I; Dasgupta A; Chopra S
Drugs Today (Barc); 2015 Feb; 51(2):117-23. PubMed ID: 25756067
[TBL] [Abstract][Full Text] [Related]
7. Delamanid or pretomanid? A Solomonic judgement!
Mudde SE; Upton AM; Lenaerts A; Bax HI; De Steenwinkel JEM
J Antimicrob Chemother; 2022 Mar; 77(4):880-902. PubMed ID: 35089314
[TBL] [Abstract][Full Text] [Related]
8. Current Status of Delamanid in the Management of MDR Tuberculosis.
Karekar SR; Marathe PA
J Assoc Physicians India; 2018 Jul; 66(7):72-75. PubMed ID: 31325268
[TBL] [Abstract][Full Text] [Related]
9. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.
Blair HA; Scott LJ
Drugs; 2015 Jan; 75(1):91-100. PubMed ID: 25404020
[TBL] [Abstract][Full Text] [Related]
10. Bedaquiline and delamanid in tuberculosis.
Esposito S; Bianchini S; Blasi F
Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803
[TBL] [Abstract][Full Text] [Related]
11. Undergraduate Medical Teaching: Time to integrate?
Ravikirti ; Sharma S
J Assoc Physicians India; 2018 Aug; 66(8):85-86. PubMed ID: 31324092
[TBL] [Abstract][Full Text] [Related]
12. Delamanid Kills Dormant Mycobacteria
Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
[TBL] [Abstract][Full Text] [Related]
13. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
14. Delamanid for multidrug-resistant pulmonary tuberculosis.
Gler MT; Skripconoka V; Sanchez-Garavito E; Xiao H; Cabrera-Rivero JL; Vargas-Vasquez DE; Gao M; Awad M; Park SK; Shim TS; Suh GY; Danilovits M; Ogata H; Kurve A; Chang J; Suzuki K; Tupasi T; Koh WJ; Seaworth B; Geiter LJ; Wells CD
N Engl J Med; 2012 Jun; 366(23):2151-60. PubMed ID: 22670901
[TBL] [Abstract][Full Text] [Related]
15. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
Matsumoto M; Hashizume H; Tomishige T; Kawasaki M; Tsubouchi H; Sasaki H; Shimokawa Y; Komatsu M
PLoS Med; 2006 Nov; 3(11):e466. PubMed ID: 17132069
[TBL] [Abstract][Full Text] [Related]
16. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.
Wen S; Jing W; Zhang T; Zong Z; Xue Y; Shang Y; Wang F; Huang H; Chu N; Pang Y
Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1293-1296. PubMed ID: 30953211
[TBL] [Abstract][Full Text] [Related]
17. Delamanid (Deltyba°) and multidrug-resistant pulmonary tuberculosis.
Prescrire Int; 2017 Apr; 26(181):89-92. PubMed ID: 30730656
[No Abstract] [Full Text] [Related]
18. MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration.
Stinson K; Kurepina N; Venter A; Fujiwara M; Kawasaki M; Timm J; Shashkina E; Kreiswirth BN; Liu Y; Matsumoto M; Geiter L
Antimicrob Agents Chemother; 2016 Jun; 60(6):3316-22. PubMed ID: 26976868
[TBL] [Abstract][Full Text] [Related]
19. Delamanid in the treatment of multidrug-resistant tuberculosis.
Gupta R; Wells CD; Hittel N; Hafkin J; Geiter LJ
Int J Tuberc Lung Dis; 2016 Dec; 20(12):33-37. PubMed ID: 28240570
[TBL] [Abstract][Full Text] [Related]
20. The Activities and Secretion of Cytokines Caused by Delamanid on Macrophages Infected by Multidrug-Resistant
Lyu XL; Lin TT; Gao JT; Jia HY; Zhu CZ; Li ZH; Dong J; Sun Q; Shu W; Pan LP; Zhang ZD; Li Q
Front Immunol; 2021; 12():796677. PubMed ID: 35003120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]